NCT06106802 2026-02-23
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Samsung Medical Center
Phase 2 Recruiting
Clinical Trials
4 trialsNCT04619004 2026-01-23
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Daiichi Sankyo
Phase 2 Active not recruiting
NCT04163432 2025-12-05
STAGGER
University of Utah
Phase 2 Active not recruiting
NCT04646824 2020-12-02
Almonertinib With Chemotherapy in mEGFR NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown